Novel Formulations and Vehicles for DAPTZ Compounds Including Methylene Blue
Summary
USPTO published patent application US20260097043A1 assigned to WisTa Laboratories Ltd., covering novel oral pharmaceutical formulations of diaminophenothiazine (DAPTZ) compounds such as methylene blue. The application discloses gastro-retentive platforms including film-coated solid tablets and buoyant self-orientating capsules with sustained-release coatings. The filing was submitted on September 20, 2023, under application number 19113777.
What changed
USPTO published patent application US20260097043A1 disclosing novel floating and gastro-retentive oral pharmaceutical compositions containing diaminophenothiazine (DAPTZ) compounds such as methylene blue. The application covers film-coated solid tablets in a gastro-retentive platform and elongate hollow cylindrical buoyant capsules with inner sustained-release and outer protective layers.
Affected parties including pharmaceutical manufacturers, drug developers, and formulation specialists should monitor this application as it may signal future competition in methylene blue and DAPTZ-based therapeutic delivery. The published application provides public notice of WisTa Laboratories' formulation technology but does not yet constitute granted patent rights.
What to do next
- Monitor for patent prosecution updates
- Contact USPTO or registered patent counsel for examination status
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NOVEL FORMULATIONS AND VEHICLES
Application US20260097043A1 Kind: A1 Apr 09, 2026
Assignee
WisTa Laboratories Ltd.
Inventors
Yin Sze Loh, John Mervyn David Storey, Claude Michel Wischik, Björn Olaf Schelter
Abstract
The invention provides different types of floating composition of diaminophenothiazine (DAPTZ) compounds such as methylene blue, which provide rapid-release in the stomach, or are gastro-retained. They further provide methods of making and using the same in the treatment and/or prevention of diseases. In one embodiment the invention provides an oral pharmaceutical composition which is a film-coated solid tablet comprising a DAPTZ compound as active ingredient in a gastro-retentive platform. In another embodiment the invention provides an oral pharmaceutical composition comprising an elongate hollow cylindrical capsule containing a weighting agent which is retained at one end, the capsule being buoyant and self-orientating, wherein the capsule is coated with an inner sustained release layer comprising a DAPTZ compound as active ingredient, and a further protective outer layer.
CPC Classifications
A61K 31/5415 A61J 1/035 A61J 1/18 A61K 9/2013 A61K 9/2018 A61K 9/2027 A61K 9/2054 A61K 9/2095 A61K 9/2813 A61K 9/282 A61K 9/2853 A61K 9/2893 A61K 9/485 A61K 9/4858 A61K 9/4866 A61K 9/4883 A61K 9/4891 A61J 2205/30
Filing Date
2023-09-20
Application No.
19113777
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.